Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.) Patents (Class 424/93.2)
  • Patent number: 10654863
    Abstract: The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: May 19, 2020
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10646563
    Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 12, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Matthew Morrow
  • Patent number: 10640784
    Abstract: The present disclosure relates, according to some embodiments, to pathogen resistant citrus compositions, organisms, systems, and methods. For example, a composition may comprise a peptide (e.g., a defensin peptide) and/or a nucleic acid (e.g., a defensin nucleic acid). A pathogen resistant citrus plant may comprise, in some embodiments, a defensin peptide and/or an expressible nucleic acid encoding a defensin peptide.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: May 5, 2020
    Assignee: The Texas A&M University System
    Inventors: T. Erik Mirkov, Kranthi Kiran Mandadi
  • Patent number: 10632153
    Abstract: The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: April 28, 2020
    Assignee: THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE
    Inventor: Jeffrey Spees
  • Patent number: 10632213
    Abstract: The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector is axonally transported in a retrograde fashion and transgene product is expressed distally to the administration site.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: April 28, 2020
    Assignee: GENZYME CORPORATION
    Inventors: Marco A. Passini, James Dodge
  • Patent number: 10626403
    Abstract: A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: April 21, 2020
    Assignee: Aviex Textnologies LLC
    Inventor: David Gordon Bermudes
  • Patent number: 10617729
    Abstract: To increase the therapeutic potential of these oncolytic viruses based on a 24 base pair deletion in the viral E1 A gene (D24), a conditionally replicating adenovirus targeting multiple receptors upregulated on tumors was generated by incorporating an Ad5/3 fiber with a carboxyl terminus RGD ligand. The virus displayed full cytopathic effect in tumor lines assayed at low titers with improved cytotoxicity over Ad5-RGD D24, Ad5/3 D24 and an HSV oncolytic virus. The virus was further engineered to deliver immunotherapeutic agents such as GMCSF while maintaining enhanced heterogenic oncolysis.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 14, 2020
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventor: George Clement Dobbins
  • Patent number: 10618944
    Abstract: The present disclosure relates to the SALL1 tumor suppressor. Methods of employing SALL1 to treat cancer, as well as the underlying mechanism by which this occurs, also are described.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 14, 2020
    Assignees: Saint Louis University, U.S. Department of Veterans Affairs
    Inventors: Guangyong Peng, Michael Rauchman, Chunling Ma, Fang Wang
  • Patent number: 10603351
    Abstract: In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: March 31, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: John C. Bell, Fabrice Le Boeuf
  • Patent number: 10588940
    Abstract: The present invention provides methods for promoting blood coagulation and/or treating blood coagulation disorders in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an angiopoietin protein or a modified angiopoietin protein molecule such as AngF1-Fc-F1 or AngF2-Fc-F2.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: March 17, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Daly, Samuel Davis
  • Patent number: 10577627
    Abstract: The present invention relates to viral vectors and methods of their production and use.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: March 3, 2020
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Robert Kotin, Jinzhao Hou, James McLaughlin
  • Patent number: 10561743
    Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: February 18, 2020
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Steven Gray, Thomas McCown
  • Patent number: 10563178
    Abstract: Compositions, methods of use and methods of manufacture are provided for PIV5-based amplifying VLP (AVLP) that can deliver an expressible heterologous nucleotide sequence in target cells without producing progeny, and which demonstrate useful safety and therapeutic efficacy in multiple animal and human health applications, such as vaccination, gene therapy and cancer therapy.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: February 18, 2020
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Biao He
  • Patent number: 10564160
    Abstract: An improved assay is described where a surface is provided with immobilized anti-Ig antibodies rather than antigen and where specific antibody-secreting cells (ASC) are detected using soluble antigen probes containing one of several possible labels. The method gives improved sensitivity with less background and is also more representative because antigen binding does not employ immobilized antigen. The assay is particularly effective for measuring antibody secreting cells against HIV, for determining whether an infection is acute as opposed to old or latent, for mapping epitopes and for measuring for ASCs against different antigens in the same reaction.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: February 18, 2020
    Assignee: MABTECH AB
    Inventors: Pia Dosenovic, Gunilla Karlsson Hedestam, Richard Wyatt, Staffan Paulie
  • Patent number: 10563208
    Abstract: The object of the invention is to provide an anaerobic enterobacterium having a higher therapeutic effect on an anaerobic site such as a solid tumor tissue and an ischemic disease site. A bacterium of the genus Bifidobacterium, which is transformed with a plasmid co-expressing two types of heterologous polypeptides and comprising two types of secretory expression cassettes each sequentially comprising a promoter DNA functioning in the bacterium of the genus Bifidobacterium; a DNA encoding a secretory signal peptide; a DNA encoding a heterologous polypeptide; and a terminator DNA functioning in the bacterium of the genus Bifidobacterium, efficiently secretes the two types of heterologous peptides, i.e., two types of antibodies having anticancer effects, outside the bacterial cell.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: February 18, 2020
    Assignee: Anaeropharma Science, Inc.
    Inventors: Koichi Koseki, Koichiro Shioya, Satoshi Kobayashi, Yuko Shimatani, Takeshi Masaki, Hitomi Shimizu, Tomio Matsumura, Masami Okabe, Kengo Inoue
  • Patent number: 10557140
    Abstract: The present invention relates to a recombinant vector, characterized by including a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)-targeting trans-splicing ribozyme expression cassette for delivery of chimeric antigen receptor, wherein the expression cassette includes: (i) a CTLA-4-targeting trans-splicing ribozyme; and (ii) a polynucleotide encoding a chimeric antigen receptor ligated to the 3? exon of the ribozyme. The present invention also relates to a transformed cell into which the recombinant vector is introduced, a ribozyme expressed from the recombinant vector, a retrovirus expressing the ribozyme, and a T cell treated with the retrovirus.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: February 11, 2020
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, DANKOOK UNIVERSITY
    Inventors: Seong Wook Lee, Bit Na Yang, Sung Jin Kim, Seung Ryul Han
  • Patent number: 10548964
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 4, 2020
    Assignee: SENTINEXT THERAPEUTICS Sdn Bhd
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Patent number: 10550378
    Abstract: Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells. Method aspects include methods for inducing apoptosis in a senescent cell comprising administering to the cell a polynucleotide, virus, host cell, or pharmaceutical composition described herein. Other methods include expressing a pro-apoptotic gene in a senescent cell comprising administering to the cell the polynucleotide, virus, or pharmaceutical composition as described herein.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: February 4, 2020
    Assignees: Unity Biotechnology, Inc., Kythera Biopharmaceuticals, Inc.
    Inventors: Serge Lichtsteiner, Nathaniel David
  • Patent number: 10544442
    Abstract: Provided are methods of estimating a volume of a biogenic gas for an area of interest. The method includes predicting a methanogenesis rate for one or more of the periods of time for the area of interest based on energy available for microbial activity and calculating the volume of the biogenic gas based on the predicted methanogenesis rate for the one or more of the periods of time for the area of interest.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 28, 2020
    Assignee: ExxonMobil Upstream Research Company
    Inventors: Michael J. Formolo, Isolde Belien, Aaron B. Regberg
  • Patent number: 10537617
    Abstract: The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: January 21, 2020
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Katherine A. High, Xavier Anguela
  • Patent number: 10532095
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 14, 2020
    Assignees: Catherex, Inc., Georgetown University, The General Hospital Corporation
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Patent number: 10532107
    Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: January 14, 2020
    Assignee: SAIBA GMBH
    Inventors: Martin Bachmann, Andris Zeltins, Paul Pumpens
  • Patent number: 10526602
    Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: January 7, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
  • Patent number: 10519205
    Abstract: Methods and compositions used to identify and characterize a new class of rhodopsins derived from algae, which are highly sensitive and efficient anion-conducting channelrhodopsins. The rhodopsin domain of these anion-conducting channelrhodopsins have been cloned and expressed in mammalian systems and thus may be used in, among others, optogenetic applications and as therapeutic agents for electrically active cell mediated disorders.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 31, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: John Lee Spudich, Elena G. Govorunova, Oleg A. Sineshchekov
  • Patent number: 10519198
    Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 31, 2019
    Assignee: California Institute of Technology
    Inventors: Benjamin E. Deverman, Paul H. Patterson, Viviana Gradinaru
  • Patent number: 10520503
    Abstract: A method for determining a likelihood of appendicitis in a subject is disclosed. The method comprises the steps of (a) determining the relative abundance of microorganisms corresponding to one or more operational taxonomic units (OTUs) in a test biological sample obtained from the subject; (b) comparing the relative abundance of the microorganisms in each of the one or more OTUs to a corresponding reference value assigned to each of the one or more OTUs, and (c) determining a likelihood of appendicitis in the subject based on the result in step (b), wherein a significant increase in relative abundance of the microorganisms in the one or more OTUs indicates a high risk of appendicitis in the subject. Also disclosed is a kit for determining a likelihood of appendicitis in a subject.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: December 31, 2019
    Assignees: CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Steven L. Zeichner, Anthony Sandler, Claire Fraser, Katherine Davenport, Emmanuel Mongodin, Hope Jackson
  • Patent number: 10512684
    Abstract: Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased T-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. a human subject, and related methods and uses.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: December 24, 2019
    Assignee: Bavarian Nordic A/S
    Inventors: Henning Lauterbach, Hubertus Hochrein, Stephanie Sanos
  • Patent number: 10508286
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: December 17, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10501755
    Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: December 10, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Kenneth E. Narva, Sarah Worden, Meghan Frey, Murugesan Rangasamy, Premchand Gandra, Wendy Lo, Elane Fishilevich, Rainer Fischer, Andreas Vilcinskas, Eileen Knorr
  • Patent number: 10501501
    Abstract: The present invention relates to novel fusion polypeptides and the uses thereof. The invention particularly relates to conjugated coat proteins derived from nepoviruses, virus-like particles made with such proteins, and the uses thereof. The particles of the invention can expose and/or encage molecules of interest and have utility in various fields such as the pharmaceutical, agro, or veterinary areas.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: December 10, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
    Inventors: Lorene Belval, Gerard Demangeat, Caroline Hemmer, Christophe Ritzenthaler
  • Patent number: 10501539
    Abstract: Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 10, 2019
    Assignees: Lentigen Technology Inc., The U.S.A., as Represented By The Secretary, Department of Health and Human Services
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Patent number: 10494619
    Abstract: Mutant mammalian RPE65 proteins and portions thereof, and nucleic acids encoding the mutants, for use in treating a condition related to retinal degeneration in a subject, the mutant mammalian RPE65 proteins or portions thereof having isomerohydrolase activity. A gene therapy method of treating a condition related to retinal degeneration in a mammalian subject in need of such treatment, comprising administering to the subject a therapeutically-effective amount of a vector comprising a nucleic acid encoding a mutant mammalian RPE65 protein or a portion thereof. A method of treating a condition related to retinal degeneration in a subject in need of such treatment, comprising administering to the subject a therapeutically-effective amount of at least one of a mutant mammalian RPE65 protein or a portion thereof.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: December 3, 2019
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Jian-Xing Ma, Yusuke Takahashi, Gennadiy Moiseyev
  • Patent number: 10494612
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: December 3, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery
  • Patent number: 10494635
    Abstract: A recombinant Herpes Simplex Virus type 1 (HSV-1) strain H129-derived anterograde multi-synaptic transneuronal viral tracer for multi-synaptic neural circuit mapping comprises two or more fluorescence expression cassettes being integrated into the H129 genome at different locations; wherein each fluorescence expression cassette contains at least two copies of fluorescent protein-encoding sequence that are arranged in tandem, and at least one linker-encoding sequence, where at least one linker-encoding sequence is disposed between two fluorescent protein-encoding sequences, allowing transcription of fluorescent protein-encoding sequences and linker-encoding sequence as a single transcript; and wherein the linker-encoding sequence encodes a linker peptide containing at least two adjacent amino acids that are highly inefficient in forming a peptide bond between them; thereby, when the single transcript is translated, at least two fluorescent proteins are stoichiometrically generated due to the impedence of pepti
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: December 3, 2019
    Assignee: Wuhan Institute of Virology, CNS
    Inventors: Minhua Luo, Wenbo Zeng, Haifei Jiang, Fei Zhao, Hong Yang, Yige Song, Zhangzhou Shen
  • Patent number: 10487123
    Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: November 26, 2019
    Assignee: Monsanto Technology LLC
    Inventors: James A. Baum, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Stanislaw Flasinski, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts, Sara A. Salvador, Jinling Wang
  • Patent number: 10465206
    Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: November 5, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Michael A. Barry, Eric Weaver
  • Patent number: 10457940
    Abstract: Aspects of the disclosure relate to compositions and methods useful for treating Huntington's disease. In some embodiments, the disclosure provides interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (HTT) and methods of treating Huntington's disease using the same.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 29, 2019
    Assignee: University of Massachusetts
    Inventors: Christian Mueller, Neil Aronin, Edith L. Pfister
  • Patent number: 10443072
    Abstract: A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3?UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3?UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3?UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 15, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Tausif Alam, Hans Sollinger
  • Patent number: 10426848
    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: October 1, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Naxin Tu, Cagan Gurer, Sean Stevens, Andrew J. Murphy
  • Patent number: 10426845
    Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional preproinsulin protein wherein the nucleotide sequence has at least 86% identity to the sequence of SEQ ID NO. 1. Also described are: vectors comprising the nucleic acid molecule for expressing the preproinsulin protein; host cells comprising the nucleic acid molecule or a vector; a transgenic animal comprising cells comprising the nucleic acid molecule or the vector; a pharmaceutical composition comprising the nucleic acid molecule or the vector; a method of treating diabetes comprising administering a therapeutically effective amount of the vector to a patient suffering from diabetes; the nucleic acid molecule for use in therapy; and the nucleic acid molecule or the vector for use in the treatment of diabetes.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 1, 2019
    Assignee: UCL Business PLC
    Inventors: Amit Nathwani, Maria Notaridou
  • Patent number: 10421977
    Abstract: This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: September 24, 2019
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Johan Karl Olov Skog, Casey Maguire
  • Patent number: 10415012
    Abstract: This disclosure describes techniques for creating stable, targeted mutations in Spirulina (Athrospiria) and Spirulina having stable, targeted mutations.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 17, 2019
    Assignee: LUMEN BIOSCIENCE, INC.
    Inventors: Ryo Takeuchi, James Roberts
  • Patent number: 10407495
    Abstract: The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: September 10, 2019
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Yong Shen
  • Patent number: 10407666
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: September 10, 2019
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Patent number: 10407695
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 10, 2019
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aude Sirven, Anne Dubart Kupperschmitt
  • Patent number: 10399291
    Abstract: The present invention provides a smart contact lens including a sensor capable of non-invasively sensing an eye disease in real time and a drug reservoir, and smart glasses for controlling the smart contact lens.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: September 3, 2019
    Assignee: PHI BIOMED CO., LTD.
    Inventors: Sei Kwang Hahn, Young Chul Sung, Beom Ho Mun, Keon Jae Lee, Dohee Keum, Su Jin Kim
  • Patent number: 10398743
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: September 3, 2019
    Assignee: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Patent number: 10398787
    Abstract: The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor IX or factor VIII genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor IX or factor VIII genes are also disclosed. The present invention is particularly useful for applications using gene therapy, in particular for the treatment of hemophilia A and B.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: September 3, 2019
    Assignee: Vrije Universiteit Brussel
    Inventors: Thierry Vandendriessche, Marinee Chuah
  • Patent number: 10391184
    Abstract: The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an rAAV particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (CSF) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the CSF for distribution to the brain.
    Type: Grant
    Filed: July 20, 2014
    Date of Patent: August 27, 2019
    Assignee: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Luis Tecedor, Yong Hong Chen
  • Patent number: 10391144
    Abstract: Embodiments of the present invention describe a method of changing the phenotype of monocytes and macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype. The method can comprises providing a composition comprising a recombinant adeno-associated virus (rAAV) vector comprising an exogenous gene encoding ApoA-I Milano or a fragment thereof, and administering the composition to a mammal in need thereof to change the phenotype of monocytes or macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype. By changing the phenotype of monocytes or macrophages from a proinflammatory M1 phenotype to an anti-inflammatory M2 phenotype, atherosclerosis can be treated. The present invention also describes a method of monitoring macrophage phenotypic switching and a method of assessing the efficacy of the treatment of atherosclerosis.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: August 27, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Prediman K. Shah, Behrooz Sharifi